← Leaderboards
Timothy J Opperman
Oscient Pharmaceuticals Corporation
$11,685,003
Attributed
$11,835,003
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,835,003 · 13
By mechanism
R44$7,104,514 · 2
R43$2,930,545 · 7
R41$1,799,944 · 4
Top collaborators
- Alejandro Pablo Heuck1 shared
Most similar at Oscient Pharmaceuticals Corporation
Same institution · by research overlap
- Donald T Moir$17,688,060
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadInfectionPathogenSeriesIn VivoCellsIn VitroPharmaceutical PreparationsResistanceAntibioticsExhibitsPropertyEvaluationBasePlayPreclinical StudyDoseInhibitor/AntagonistAnalogAnti-Bacterial AgentsBacteriaDrug DesignEscherichia ColiCytotoxicity
Grant awards (26)
Proof of concept experiments for T3SS inhibitors against burn wound infections$300,000
R41 · FY2025 · AI · contact PI
Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections$299,946
R41 · FY2025 · AI · contact PI
Proof of concept experiments for T3SS inhibitors against burn wound infections$300,000
R41 · FY2024 · AI · contact PI
Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis$300,156
R43 · FY2022 · EY · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$1,000,000
R44 · FY2021 · AI · contact PI
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa$300,000
R41 · FY2021 · AI · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$981,076
R44 · FY2020 · AI · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$987,681
R44 · FY2019 · AI · contact PI
Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance$294,798
R43 · FY2018 · AI · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$742,587
R44 · FY2017 · AI · contact PI
Inhibitors of Pseudomonas aeruginosa efflux pumps to combat multi-drug resistance$299,342
R43 · FY2017 · AI · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$783,116
R44 · FY2016 · AI · contact PI
Optimization of novel pyranopyridine efflux pump inhibitors$961,043
R44 · FY2015 · AI · contact PI
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus$295,399
R43 · FY2013 · AI · contact PI
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus$300,000
R43 · FY2012 · AI · contact PI
A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION$299,999
R41 · FY2012 · AI · contact PI
Novel aryl-rhodanine inhibitors of Streptococcus mutans biofilms$168,214
R43 · FY2012 · DE · contact PI
A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION$299,999
R41 · FY2011 · AI · contact PI
Antibiotic Potentiators Targeting SOS Induction$300,000
R43 · FY2009 · AI · contact PI
Antibiotic Potentiators Targeting SOS Induction$300,000
R43 · FY2008 · AI · contact PI
c-diGMP Signal Transduction Proteins are Biofilm Drug Targets$367,815
R43 · FY2006 · HL · contact PI
Novel Therapies for BioFilm-Related Infections$892,465
R44 · FY2005 · AI
THERAPEUTIC APPROACHES TO BIOFILM ANTIBIOTIC RESISTANCE$304,821
R43 · FY2005 · HL
Novel Therapies for BioFilm-Related Infections$710,003
R44 · FY2004 · AI
Novel Therapies for BioFilm-Related Infections$25,573
R44 · FY2003 · AI
Novel Therapies for BioFilm-Related Infections$20,970
R44 · FY2003 · AI